Advertising jury on warnings for medical products
With decision number 7/2013 issued on 8 February 2013, in the case Boheringer Ingeheim Italia S.p.A. v Verelibron S.r.l./Chefaro Pharma Italia S.r.l., the Advertising and Marketing Communication Self-Regulation Authority took position on the interpretation of section 25 of the Self Regulation Code of Marketing Communication relating to the advertisement of medical products and curative treatments. Said provision ‘requires to deliver an express invitation to read the package warnings in advertisements’.
Boheringer claimed that the respondent’s TV commercial for a cough syrup was misleading and not compliant with section 25 of the Code. Boheringer argued that the invitation to read the package warnings was not given orally but with a dateline that was unable to draw consumer’s attention.
If you are registered and logged in to the site, click on the link below to read the rest of the NCTM briefing. If not, please register or sign in with your details below.
News from NCTM
Briefings from NCTM
One of the EPO Boards of Appeal has ruled on the highly debated issue of human stem cell patentability under the European Patent Convention.
On 7 February 2014, the European Court of Justice (Case 98-13) issued a ruling pertaining to the interpretation of Council Regulation (EC) no. 1383/2003.
Analysis from The Lawyer
Being sent to London on secondment is a prized opportunity for associates in European firms